Nautilus Biotechnology A

Nautilus Biotechnology reported Q1 2026 EPS of -0.12 versus a forecast of -0.17, beating expectations by 29.41%. The stock rose 11.63% in premarket trading. Operating expenses fell 14% year over year to $16.1 million, cash on hand is $143.4 million and is expected to fund the company through 2027. The company plans strategic hires and commercialization efforts with product launches toward the end of 2026, expects revenue of about $0.5 million for 2026, and cites risks of delays in revenue recognition. » Więcej na de.investing.com

Nautilus Biotechnology presented the Voyager proteomics platform at an investor conference, with an early-access beta planned for H2 2026, along with partnerships and a focus on tau and oncology proteoform assays. The company reports a liquid cash position of $156 million, which is expected to fund operations through 2027. Forecasts project a proteomics market with a 13% CAGR through 2030 and an expected customer spend rate on consumables of around $500,000 per year. » Więcej na de.investing.com

At an investor conference, Nautilus Biotechnology presented its iterative mapping technology for complete proteome analysis and positions itself as a disruptive force in drug development. The platform is slated to launch at the end of 2026 at about $1 million per instrument; consumables are expected to cost a few thousand dollars per sample. The company cites an addressable market of $57 billion by 2030, holds $180 million in cash (sufficient through the end of 2027), and anticipates further funding rounds to scale. A collaboration with the Allen Institute is intended to validate applications for neurodegenerative diseases such as Alzheimer’s. » Więcej na de.investing.com